MEN 10207, also known as [Tyr5,D-Trp6,8,9,Arg10]-Neurokinin A (4-10), is a seven-residue synthetic tachykinin analog developed as a selective peptide antagonist of the NK2 receptor.

Its sequence, Asp-Tyr-D-Trp-Val-D-Trp-D-Trp-Arg-NH₂, differs extensively from native NKA (4-10) and contains three D-tryptophan residues that are central to its antagonist pharmacology.

Product Information

Three D-Trp Residues Drive the Antagonist Scaffold

MEN 10207 replaces several residues from native NKA(4-10) with bulky aromatic D-tryptophans. Structure–activity studies showed that the simultaneous presence of all three D-Trp residues is important for both receptor affinity and NK2 selectivity.

NK2-Selective Tachykinin Antagonism

MEN 10207 has been used to block NKA-mediated responses in recombinant receptor and smooth-muscle systems. Its pharmacological profile is substantially different from the agonist behavior of native Neurokinin A.

Published potency values are assay-specific and should be treated as reference pharmacology rather than batch specifications.

A Direct SAR Partner for NKA (4-10)

Because both molecules contain seven residues, comparing MEN 10207 with NKA (4-10) provides a compact system for examining how stereochemistry, aromaticity and C-terminal charge can convert an agonist-derived scaffold into an antagonist.

Frequently Asked Questions

Is MEN 10207 an NK2 agonist?

No. It is primarily characterized as an NK2-selective peptide antagonist.

Why are the D-Trp residues important?

Experimental substitution studies showed that the three D-Trp residues collectively contribute strongly to affinity and selectivity.

Research Use Only.